Cargando…
Evaluation of tumour surveillance protocols and outcomes in von Hippel-Lindau disease in a national health service
BACKGROUND: Von Hippel-Lindau (VHL) disease is an inherited tumour predisposition syndrome and a paradigm for the importance of early diagnosis and surveillance. However, there is limited information on the “real world” management of VHL disease. METHODS: A national audit of VHL disease in the Unite...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8857742/ https://www.ncbi.nlm.nih.gov/pubmed/35184155 http://dx.doi.org/10.1038/s41416-022-01724-7 |
_version_ | 1784654104010686464 |
---|---|
author | Maher, Eamonn R. Adlard, Julian Barwell, Julian Brady, Angela F. Brennan, Paul Cook, Jackie Crawford, Gillian S. Dabir, Tabib Davidson, Rosemarie Dyer, Rebecca Harrison, Rachel Forde, Claire Halliday, Dorothy Hanson, Helen Hay, Eleanor Higgs, Jenny Jones, Mari Lalloo, Fiona Miedzybrodzka, Zosia Ong, Kai Ren Pelz, Frauke Ruddy, Deborah Snape, Katie Whitworth, James Sandford, Richard N. |
author_facet | Maher, Eamonn R. Adlard, Julian Barwell, Julian Brady, Angela F. Brennan, Paul Cook, Jackie Crawford, Gillian S. Dabir, Tabib Davidson, Rosemarie Dyer, Rebecca Harrison, Rachel Forde, Claire Halliday, Dorothy Hanson, Helen Hay, Eleanor Higgs, Jenny Jones, Mari Lalloo, Fiona Miedzybrodzka, Zosia Ong, Kai Ren Pelz, Frauke Ruddy, Deborah Snape, Katie Whitworth, James Sandford, Richard N. |
author_sort | Maher, Eamonn R. |
collection | PubMed |
description | BACKGROUND: Von Hippel-Lindau (VHL) disease is an inherited tumour predisposition syndrome and a paradigm for the importance of early diagnosis and surveillance. However, there is limited information on the “real world” management of VHL disease. METHODS: A national audit of VHL disease in the United Kingdom. RESULTS: VHL disease was managed mostly via specialist clinics coordinated through regional clinical genetics services (but frequently involving additional specialties). Over the study period, 19 genetic centres saw 842 individuals (393 males, 449 females) with a clinical and/or molecular diagnosis of VHL disease and 74 individuals (35 male, 39 female) with a prior risk of 50% (affected parent). All centres offered retinal, central nervous system and abdominal surveillance to affected individuals and at-risk relatives though surveillance details differed between centres (but complied with international recommendations). Renal lesions detected on the first surveillance scan were, on average, larger than those detected during subsequent scans and the larger the diameter at detection the greater the likelihood of early intervention. CONCLUSIONS: In a state-funded health care system individuals with a rare inherited cancer predisposition syndrome are generally able to access appropriate surveillance and patient management is improved compared to historical data. The “real world” data from this study will inform the future development of VHL management protocols. |
format | Online Article Text |
id | pubmed-8857742 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-88577422022-02-22 Evaluation of tumour surveillance protocols and outcomes in von Hippel-Lindau disease in a national health service Maher, Eamonn R. Adlard, Julian Barwell, Julian Brady, Angela F. Brennan, Paul Cook, Jackie Crawford, Gillian S. Dabir, Tabib Davidson, Rosemarie Dyer, Rebecca Harrison, Rachel Forde, Claire Halliday, Dorothy Hanson, Helen Hay, Eleanor Higgs, Jenny Jones, Mari Lalloo, Fiona Miedzybrodzka, Zosia Ong, Kai Ren Pelz, Frauke Ruddy, Deborah Snape, Katie Whitworth, James Sandford, Richard N. Br J Cancer Article BACKGROUND: Von Hippel-Lindau (VHL) disease is an inherited tumour predisposition syndrome and a paradigm for the importance of early diagnosis and surveillance. However, there is limited information on the “real world” management of VHL disease. METHODS: A national audit of VHL disease in the United Kingdom. RESULTS: VHL disease was managed mostly via specialist clinics coordinated through regional clinical genetics services (but frequently involving additional specialties). Over the study period, 19 genetic centres saw 842 individuals (393 males, 449 females) with a clinical and/or molecular diagnosis of VHL disease and 74 individuals (35 male, 39 female) with a prior risk of 50% (affected parent). All centres offered retinal, central nervous system and abdominal surveillance to affected individuals and at-risk relatives though surveillance details differed between centres (but complied with international recommendations). Renal lesions detected on the first surveillance scan were, on average, larger than those detected during subsequent scans and the larger the diameter at detection the greater the likelihood of early intervention. CONCLUSIONS: In a state-funded health care system individuals with a rare inherited cancer predisposition syndrome are generally able to access appropriate surveillance and patient management is improved compared to historical data. The “real world” data from this study will inform the future development of VHL management protocols. Nature Publishing Group UK 2022-02-19 2022-05-18 /pmc/articles/PMC8857742/ /pubmed/35184155 http://dx.doi.org/10.1038/s41416-022-01724-7 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. (https://creativecommons.org/licenses/by/4.0/) |
spellingShingle | Article Maher, Eamonn R. Adlard, Julian Barwell, Julian Brady, Angela F. Brennan, Paul Cook, Jackie Crawford, Gillian S. Dabir, Tabib Davidson, Rosemarie Dyer, Rebecca Harrison, Rachel Forde, Claire Halliday, Dorothy Hanson, Helen Hay, Eleanor Higgs, Jenny Jones, Mari Lalloo, Fiona Miedzybrodzka, Zosia Ong, Kai Ren Pelz, Frauke Ruddy, Deborah Snape, Katie Whitworth, James Sandford, Richard N. Evaluation of tumour surveillance protocols and outcomes in von Hippel-Lindau disease in a national health service |
title | Evaluation of tumour surveillance protocols and outcomes in von Hippel-Lindau disease in a national health service |
title_full | Evaluation of tumour surveillance protocols and outcomes in von Hippel-Lindau disease in a national health service |
title_fullStr | Evaluation of tumour surveillance protocols and outcomes in von Hippel-Lindau disease in a national health service |
title_full_unstemmed | Evaluation of tumour surveillance protocols and outcomes in von Hippel-Lindau disease in a national health service |
title_short | Evaluation of tumour surveillance protocols and outcomes in von Hippel-Lindau disease in a national health service |
title_sort | evaluation of tumour surveillance protocols and outcomes in von hippel-lindau disease in a national health service |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8857742/ https://www.ncbi.nlm.nih.gov/pubmed/35184155 http://dx.doi.org/10.1038/s41416-022-01724-7 |
work_keys_str_mv | AT mahereamonnr evaluationoftumoursurveillanceprotocolsandoutcomesinvonhippellindaudiseaseinanationalhealthservice AT adlardjulian evaluationoftumoursurveillanceprotocolsandoutcomesinvonhippellindaudiseaseinanationalhealthservice AT barwelljulian evaluationoftumoursurveillanceprotocolsandoutcomesinvonhippellindaudiseaseinanationalhealthservice AT bradyangelaf evaluationoftumoursurveillanceprotocolsandoutcomesinvonhippellindaudiseaseinanationalhealthservice AT brennanpaul evaluationoftumoursurveillanceprotocolsandoutcomesinvonhippellindaudiseaseinanationalhealthservice AT cookjackie evaluationoftumoursurveillanceprotocolsandoutcomesinvonhippellindaudiseaseinanationalhealthservice AT crawfordgillians evaluationoftumoursurveillanceprotocolsandoutcomesinvonhippellindaudiseaseinanationalhealthservice AT dabirtabib evaluationoftumoursurveillanceprotocolsandoutcomesinvonhippellindaudiseaseinanationalhealthservice AT davidsonrosemarie evaluationoftumoursurveillanceprotocolsandoutcomesinvonhippellindaudiseaseinanationalhealthservice AT dyerrebecca evaluationoftumoursurveillanceprotocolsandoutcomesinvonhippellindaudiseaseinanationalhealthservice AT harrisonrachel evaluationoftumoursurveillanceprotocolsandoutcomesinvonhippellindaudiseaseinanationalhealthservice AT fordeclaire evaluationoftumoursurveillanceprotocolsandoutcomesinvonhippellindaudiseaseinanationalhealthservice AT hallidaydorothy evaluationoftumoursurveillanceprotocolsandoutcomesinvonhippellindaudiseaseinanationalhealthservice AT hansonhelen evaluationoftumoursurveillanceprotocolsandoutcomesinvonhippellindaudiseaseinanationalhealthservice AT hayeleanor evaluationoftumoursurveillanceprotocolsandoutcomesinvonhippellindaudiseaseinanationalhealthservice AT higgsjenny evaluationoftumoursurveillanceprotocolsandoutcomesinvonhippellindaudiseaseinanationalhealthservice AT jonesmari evaluationoftumoursurveillanceprotocolsandoutcomesinvonhippellindaudiseaseinanationalhealthservice AT lalloofiona evaluationoftumoursurveillanceprotocolsandoutcomesinvonhippellindaudiseaseinanationalhealthservice AT miedzybrodzkazosia evaluationoftumoursurveillanceprotocolsandoutcomesinvonhippellindaudiseaseinanationalhealthservice AT ongkairen evaluationoftumoursurveillanceprotocolsandoutcomesinvonhippellindaudiseaseinanationalhealthservice AT pelzfrauke evaluationoftumoursurveillanceprotocolsandoutcomesinvonhippellindaudiseaseinanationalhealthservice AT ruddydeborah evaluationoftumoursurveillanceprotocolsandoutcomesinvonhippellindaudiseaseinanationalhealthservice AT snapekatie evaluationoftumoursurveillanceprotocolsandoutcomesinvonhippellindaudiseaseinanationalhealthservice AT whitworthjames evaluationoftumoursurveillanceprotocolsandoutcomesinvonhippellindaudiseaseinanationalhealthservice AT sandfordrichardn evaluationoftumoursurveillanceprotocolsandoutcomesinvonhippellindaudiseaseinanationalhealthservice |